Microwave ablation and combined with adoptive immunotherapy for hepatocellular carcinoma

ZHOU Pei,LIANG Ping,DONG Bao-wei,YU Xiao-ling,YU Jie,XU Ying-xin
DOI: https://doi.org/10.3969/j.issn.1008-0392.2012.04.016
2012-01-01
Abstract:Objective To assess the safety and the levels of peripheral T lymphocyte subsets in patients with hepatocellular carcinoma(HCC)undergoing percutaneous microwave ablation(PMWA)combined with adoptive immunotherapy.Methods Ten patients with HCC(D≤5cm,less than 3 tumors)were treated with radical PMWA and adoptive immunotherapy(combination group).The immunotherapy was administrated at d0,d11 and d100 after PMWA,respectively.During the immunotherapy immature DCs,cytokine-induced killer cells(CIKs)and cytotoxic T lymphocytes(CTs)were injected into the marginal area of ablated tumors under contrast-enhanced sonographic guidance,and the tumor lysate-pulsed DCs were injected into groin lymph nodes,while DC-CIKs and CTLs were injected into the abdominal cavity,CIKs was infused intravenously.Other 24 HCC patients were treated with PMWA alone(PMWA group).Results No adverse effects of grade Ⅲ/Ⅳ were observed.The percentage of CD4+CD25high regulatory T lymphocytes decreased significantly and was significantly lower than those in PMWA group;the percentage of CD8+CD28+and CD8+CD28-effector cells increased significantly,the percentage of CD8+CD28+of combination group was significantly higher than that of PMWA group;the CD4+/CD8+ decreased significantly and was significantly lower than that of PMWA group 1month after therapy.Six months after therapy,only the percentage of CD8+CD28+and CD4+/CD8+of the combination group had significant difference with those of PMWA group and those before treatment.Conclusion Adoptive immunotherapy combined with PMWA is safe and can improve the immune status for patients with HCC.
What problem does this paper attempt to address?